ANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2016 Highlights and Reaffirms Updated Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
ANI Pharmaceuticals (ANIP) PT Lifted to $55 at Guggenheim
May 5, 2016 10:18 AM EDTGuggenheim analyst Louise Chen reiterating Buy rating and boosted his price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $55.00 (from $50.00) following Q1 beat. The analyst sees many potential catalysts in 2Q16+.
Chen commented, "Post the 1Q16 beat, we remain positive on ANIP and... More
ANI Pharma (ANIP) Tops Q1 EPS by 12c, Offers FY16 Guidance
May 5, 2016 9:29 AM EDTANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $0.76, $0.12 better than the analyst estimate of $0.64. Revenue for the quarter came in at $20.6 million versus the consensus estimate of $21.03 million.
GUIDANCE:
ANI Pharma sees FY2016 EPS of $3.54-$3.91, versus the consensus... More
